MetLife Investment Management’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-616
| Closed | -$65.6K | – | 2903 |
|
|
2023
Q2 | $65.6K | Hold |
616
| – | – | ﹤0.01% | 2864 |
|
|
2023
Q1 | $184K | Hold |
616
| – | – | ﹤0.01% | 2270 |
|
|
2022
Q4 | $212K | Hold |
616
| – | – | ﹤0.01% | 2213 |
|
|
2022
Q3 | $116K | Hold |
616
| – | – | ﹤0.01% | 2601 |
|
|
2022
Q2 | $130K | Hold |
616
| – | – | ﹤0.01% | 2584 |
|
|
2022
Q1 | $206K | Buy |
616
+224
| +57% | +$74.9K | ﹤0.01% | 2340 |
|
|
2021
Q4 | $128K | Hold |
392
| – | – | ﹤0.01% | 2317 |
|
|
2021
Q3 | $190K | Buy |
392
+84
| +27% | +$40.8K | ﹤0.01% | 2124 |
|
|
2021
Q2 | $143K | Hold |
308
| – | – | ﹤0.01% | 2343 |
|
|
2021
Q1 | $213K | Hold |
308
| – | – | ﹤0.01% | 2023 |
|
|
2020
Q4 | $227K | Hold |
308
| – | – | ﹤0.01% | 1913 |
|
|
2020
Q3 | $214K | Hold |
308
| – | – | ﹤0.01% | 1828 |
|
|
2020
Q2 | $261K | Buy |
+308
| New | +$261K | ﹤0.01% | 1744 |
|